Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 45% Improvement Relative Risk Ventilation 42% ICU admission 37% c19early.org/d Derakhshanian et al. Vitamin D for COVID-19 Sufficiency Favors vitamin D Favors control
The predictive power of serum vitamin D for poor outcomes in COVID-19 patients
Derakhshanian et al., Food Science & Nutrition, doi:10.1002/fsn3.2591
Derakhshanian et al., The predictive power of serum vitamin D for poor outcomes in COVID-19 patients, Food Science & Nutrition, doi:10.1002/fsn3.2591
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 290 hospitalized patients in Iran, showing higher mortality with vitamin D deficiency.
risk of death, 44.8% lower, RR 0.55, p = 0.046, high D levels 148, low D levels 142, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, control prevalance approximated with overall prevalence.
risk of mechanical ventilation, 41.7% lower, RR 0.58, p = 0.09, high D levels 148, low D levels 142, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, control prevalance approximated with overall prevalence.
risk of ICU admission, 37.3% lower, RR 0.63, p = 0.04, high D levels 148, low D levels 142, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, control prevalance approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Derakhshanian et al., 19 Sep 2021, retrospective, Iran, peer-reviewed, 11 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Received: 29 January 2021 | Revised: 26 August 2021 | Accepted: 27 August 2021 DOI: 10.1002/fsn3.2591 ORIGINAL RESEARCH The predictive power of serum vitamin D for poor outcomes in COVID-­19 patients Hoda Derakhshanian1,2 | Hadith Rastad3 | Sanjoy Ghosh4 | Marjan Zeinali5 | Mahsa Ziaee5 | Tara Khoeini5 | Mohsen Farrokhpour6 | Mostafa Qorbani3 | 7 8 5,9 Mona Ramezani Ghamsari | Hossein Hasani | Zahra Mirzaasgari 1 Department of Biochemistry Genetics and Nutrition, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran 2 Abstract Considering the high prevalence of vitamin D deficiency worldwide and its rela- Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran tionship with immune response to viral infections, this study attempted to identify 3 patients. This retrospective cohort study included all patients with confirmed Non-­communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran 4 Department of Biology Okanagan Campus, University of British Columbia, Kelowna, BC, Canada 5 Department of Neurology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran 6 Department of Internal Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran 7 Clinical Research Development Unit, Shahid Rajaei Educational and Medical Center, Alborz University of Medical Sciences, Karaj, Iran 8 Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran 9 Shefa Neuroscience Research Center, Tehran, Iran Correspondence Zahra Mirzaasgari, Department of Neurology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran. Email: mirzaasgari@gmail.com the predictive power of serum vitamin D for poor outcomes among the COVID-­19 COVID-­19 hospitalized between February 20, 2020, and April 20, 2020, at a designated COVID-­19 hospital, located in Tehran province, Iran. General characteristics, medical history and clinical symptoms were recorded by trained physicians. Blood parameters including complete blood count, creatinine, lactate dehydrogenase, creatine phosphokinase, erythrocyte sedimentation rate, C-­reactive protein and vitamin D were tested. This study included 290 hospitalized patients with COVID-­19 (the mean age [SD]: 61.6 [16.9], 56.6% males), of whom 142 had vitamin D concentrations less than 20 ng/ml, defined as vitamin D deficiency. COVID-­19 patients with vitamin D deficiency were more likely to die (Crude OR [95% CI]: 2.30 [1.25–­4.26]), require ICU (2.06 [1.22–­3.46]) and invasive mechanical ventilation (2.03 [1.04–­3.93]) based on univariate logistic regression results. Although, after adjusting for potentials confounders such as gender and age, the association between vitamin D and need to invasive mechanical ventilation lost its significance, adjusted values for the risk of death and ICU requirement were still statistically significant. Vitamin D deficiency can be considered as a predictor of poor outcomes and mortality in COVID-­19 patients. Therefore, checking serum 25 (OH) D on admission and taking vitamin D supplements according to the prophylactic or treatment protocols is recommended for all COVID-­19 patients. KEYWORDS Funding information This study was funded by Iran University of Medical Sciences and Alborz University of Medical Sciences coronavirus infections, COVID-­19, SARS-­CoV-­2, vitamin D This..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit